Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

venous thrombosis - antithrombotics - all type of patients  


Related trials

Lopaciuk, 3000 - subcutaneous heparin vs intravenous heparin

RE-COVER, 2009 - dabigatran vs vitamin K antagonists

Romera, 2009 - Tinzaparin vs acenocoumarol

González-Fajardo, 2008 - Enoxaparin vs coumarin

Botticelli DVT, 2008 - apixaban vs heparin/VKA

Einstein-DVT Dose-Ranging Study, 2008 - rivaroxaban vs heparin/VKA

VanGogh DVT, 2007 - idraparinux vs heparin/VKA

VanGogh PE, 2007 - idraparinux vs heparin/VKA

Daskalopoulos, 2005 - LMWH at home vs UFH in hospital

Fiessinger , 2005 - ximelagatran vs vitamin K antagonists

Chong, 2005 - LMWH at home vs UFH in hospital

Kearon, 2004 - 4 months vs 3 months

Ramacciotti, 2004 - LMWH at home vs UFH in hospital

MATISSE, 2004 - fondaparinux vs enoxaparin

Lee, 2003 - Dalteparin vs warfarin

Agnelli, 2003 - 6-12 months vs 3 months

Kakkar, 2003 - Bemiparin vs warfarin

Deitcher, 2003 - Enoxaparin vs warfarin

MATISSE PE, 2003 - fondaparinux vs heparin/VKA

Hull, 2002 - Tinzaparin vs warfarin

Meyer, 2002 - Enoxaparin vs warfarin

Agnelli, 2001 - 12 months vs 3 months

Merli (once daily vs UFH), 2001 - once daily enoxaparin vs UFH

Lopez-Beret, 2001 - Nadroparin vs acenocoumarol

Merli, 2001 - once daily enoxaparin vs twice daily enoxaparin



See also:

  • All venous thrombosis clinical trials
  •  

    VanGogh DVT study, 2007

    [NCT00067093]

    Treatments

    Studied treatment subcutaneous idraparinux (2.5 mg once weekly)
    Control treatment heparin followed by an adjusted-dose vitamin K antagonist

    Patients

    Patients patients with deep-vein thrombosis
    Inclusion criteria calf trifurcation or more proximal vein that was not compressible on ultrasonography or an intraluminal filling defect on venography
    Exclusion criteria therapeutic dose of low-molecular-weight heparin or unfractionated heparin administered for more than 36 hours before randomization; thrombolysis, embolectomy, or vena cava filter required for the current episode; another indication for a vitamin K antagonist; pregnancy or breast-feeding; creatinine clearance of less than 10 ml per minute; uncontrolled hypertension (systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg); life expectancy of less than 3 months.
    Baseline characteristics
    Age 58.4 y 
    female (%) 66 % 
    Time from onset of symptoms 8.2 days 
    cancer (%) 14.5 % 
    Immobilization (%) 6.6% 

    Method and design

    Randomized effectives 1452 / 1452 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 3 mo (6 mo)
    Hypothesis Non inferiority
    Primary endpoint 3-month incidence of symptomatic recurrent venous thromboembolism (nonfatal or fatal)


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    Recurrent thromboembolic event

    42 / 1452
    43 / 1452
    0,98 [0,64;1,48]

    Bleeding

    65 / 1452
    101 / 1452
    0,64 [0,48;0,87]

    All cause death

    33 / 1452
    32 / 1452
    1,03 [0,64;1,67]

    Major bleeding

    12 / 1452
    17 / 1452
    0,71 [0,34;1,47]

    recurrent VTE during treatment

    42 / 1452
    43 / 1452
    0,98 [0,64;1,48]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Studied treat. Control treat.
    Recurrent thromboembolic event 42 / 1452 (2,9%) 43 / 1452 (3,0%) 0,98 [0,64;1,48] at day 92 
    Bleeding 65 / 1452 (4,5%) 101 / 1452 (7,0%) 0,64 [0,48;0,87] any clinically relevant bleeding at day 92 
    Major bleeding 12 / 1452 (0,8%) 17 / 1452 (1,2%) 0,71 [0,34;1,47] at day 92 
    recurrent VTE during treatment 42 / 1452 (2,9%) 43 / 1452 (3,0%) 0,98 [0,64;1,48] at day 92 
    All cause death 33 / 1452 (2,3%) 32 / 1452 (2,2%) 1,03 [0,64;1,67] at day 92 
    The primary endpoint (if exists) appears in blod characters

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Recurrent thromboembolic event 2,89% 2,96% -0,7‰
    Bleeding 4,48% 6,96% -24,8‰
    Major bleeding 8,26‰ 1,17% -3,4‰
    recurrent VTE during treatment 2,89% 2,96% -0,7‰
    All cause death 2,27% 2,20% 0,7‰


    Reference(s)

    Trials register # NCT00067093
    • Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. . N Engl J Med 2007 Sep 13;357:1094-104
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend